MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, according to the company’s website www.MabVax.com.
In this SNNLive In-Studio Video Interview, our host caught up with David Hansen, President and CEO of MabVax Therapeutics Holdings, Inc., on August 22nd, 2016 from our studio in Los Angeles, CA, and they discuss the following topics:
- Overview of MabVax Therapeutics Holdings, Inc.
- Diagnostics business
- Partnership with Memorial Sloan Kettering Cancer Center
- Clinical developments
- The company’s biotechnology
- Goals and milestones for 2016
- Update since our last interview
- Corporate developments
- Management and Mr. Hansen’s background
- Where the science was developed
For more information about MabVax Therapeutics Holdings, Inc., please visit: www.MabVax.com
The interview may contain forward-looking statements about MabVax Therapeutics Holdings, Inc. See MabVax Therapeutics Holdings' periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions